FdaApplication
NDA 210450
Identifiers
- fda_app_no: NDA210450
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2018-07-23 |
Revenue by product
ORILISSA
| Period | Revenue |
|---|---|
| Q4 2021 | $39.0M* |
| Q3 2021 | $38.0M* |
| Q2 2021 | $38.0M* |
| Q1 2021 | $30.0M* |
| Q4 2020 | $38.0M* |
| Q3 2020 | $25.0M* |
| Q2 2020 | $31.0M* |
| Q1 2020 | $62.0M* |
| Q4 2019 | $68.0M* |
| Q3 2019 | $54.0M* |
| Q2 2019 | $38.0M* |
| Q1 2019 | $13.0M |
| Q4 2018 | $8.0M |
| Q3 2018 | $3.0M |
| Q2 2018 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ORILISSA | ELAGOLIX SODIUM | EQ 150MG BASE | TABLET;ORAL |
| ORILISSA | ELAGOLIX SODIUM | EQ 200MG BASE | TABLET;ORAL |
2 products